Martek Plans 2011 Supplement Launches Through Amerifit Subsidiary
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences' dietary supplement pipeline comes into focus as the developer of algae-based omega-3 oils lines up a slate of products to launch in 2011 through its Amerifit Brands business
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.
DSM's $1.1B Martek Acquisition Comes With Potential IP Expirations
Dutch ingredients giant Royal DSM N.V. incurs no incremental risk in acquiring Martek Biosciences despite the looming expiration dates for Martek's intellectual property, according to a market analyst.